First International Forum on Cell Biopharmaceutical Technology and Industrial Development Successfully Held in Baoshan, Shanghai
On May 27, the First Cell Biopharmaceutical Technology and Industry Development Forum was held in the Baoshan High-Tech Zone in Shanghai. Themed “Forging New Momentum in Cell Technology to Fully Support Baoshan’s Northern Transformation,” the forum brought together leaders and experts from government, academia, research institutions, healthcare, and business sectors to discuss R&D progress in the cell industry and explore emerging trends in its future development.
Han Zhongchao, Member of the French Academy of Sciences and Academia Europaea, Director of the National Engineering Research Center for Stem Cell Technology, and Chief Scientist of Han’s United; Fu Xiaobing, Academician of the Chinese Academy of Engineering, Foreign Associate of the U.S. National Academy of Engineering, Dean of the School of Life Sciences at the PLA General Hospital, and Member of the National Committee of the Chinese People's Political Consultative Conference; Georges UZAN, Member of the French National Academy of Medicine and Director of the Institute 972 of the French National Academy of Medicine; Shi Yufang, Member of Academia Europaea and Director of the Jiangsu Provincial Key Laboratory of Stem Cells and Biomedical Materials; as well as representatives from relevant commissions, offices, and bureaus of Baoshan District and the Management Committee of Baoshan High-Tech Park attended the forum.
Conference Venue
Liu Huibin, Director of the Administrative Committee of Baoshan High-Tech Zone, stated that the park has been deeply engaged in the biomedical industry for many years, initially establishing specialized industrial clusters in medical devices, biotechnology, and new healthcare services. This has created a brand effect both in Shanghai and across China, with industrial competitiveness gradually becoming more prominent. Cell-based biomedicine represents the forefront of biotechnology and is a key technology concerning public health. Leveraging this forum as an opportunity, the park will focus on the niche sector of cell biology, utilizing robust policy support, efficient innovation services, and a comprehensive innovation system to continuously strengthen and expand the biomedical industry.
Address by Director Liu Huibin
Professor Han Zhongchao, Academician of the French National Academy of Technologies, Foreign Corresponding Member of the French National Academy of Medicine, and Director of the National Engineering Research Center for Stem Cell Technology, stated that HANCELLS has achieved many gratifying results in the field of regenerative medicine over the years. In recent years, it has established a complete ecological chain spanning research and development, production, and terminal services. As an emerging enterprise rooted in HANCELLS, specializing in full-lifecycle health management and industrial park operations, Sinocell Group is based in Baoshan, serving China, and facing the world, striving to fulfill its mission in driving the northern transformation.
Address by Academician Han Zhongchao
Director Ding Jianping's Recommendation
Ding Jianping, Director of the Baoshan District Science and Technology Innovation Commission, introduced the district’s industrial development landscape and investment promotion policies. The biopharmaceutical sector has long been a strategic emerging industry prioritized for development in Baoshan. We welcome more entrepreneurs to choose Baoshan, invest in its construction, deepen their roots here, and achieve mutual growth and a win-win future with the district.
Leveraging the strong platform of the 1st Cell Biopharmaceutical Technology and Industry Development Forum, an on-site signing ceremony for stationing at the industrial base was held to attract more enterprises to settle in the International Comprehensive Cell Biopharmaceutical Industry Base and promote mutual development.
Representatives from Tianjin Angsai Cell & Gene Engineering Co., Ltd. and Beijing Health & Harmony Biotechnology Co., Ltd. signed an agreement with the Administrative Committee of Baoshan High-Tech Industrial Development Zone.
Shanghai Sinovant Life Health Technology Co., Ltd. signed industry-academia-research and financial cooperation agreements with the Heart and Brain Science Laboratory of the Business School at East China University of Science and Technology, the School of Materials Engineering at Shanghai University of Engineering Science, Shanghai Normal University, Zhongke Ruiji, and the Baoshan Sub-branch of Industrial and Commercial Bank of China.
Experts from academia, industry, healthcare, capital, and law convened to focus on the fields of biopharmaceuticals and intelligent diagnostics. They jointly explored the opportunities and challenges facing the industry, as well as future industrial layout and investment directions, contributing their expertise to sci-tech innovation in Baoshan and presenting attendees with an academic feast on cellular biopharmaceuticals.
Academician Han Zhongchao Presents “Research, Development, and Application of Mesenchymal Stem Cell Products”
Academician Fu Xiaobing Delivers a Presentation on “Original Aspiration and Mission: A Review and Prospects for the Construction of a Wound Repair Discipline System with Chinese Characteristics”
Academician Georges UZAN Presents on “The Value of Circulating Tumor Cell Analysis in Clinical Oncology”
Academician Shi Yufang Delivers a Presentation on “Tissue Inflammatory Microenvironment and Regeneration”
At the event, guests delivered keynote speeches on “Stem Cells and Regenerative Medicine” and “Allogeneic Transplantation and Immunotherapy.”
Professor Tao Yong Delivers a Presentation on “Research on the Use of Exosomes in the Treatment of Ocular Diseases”
Professor Han Ying Shares Insights on “Reflections on Stem Cell Therapy for Liver Diseases”
Professor Zhou Bin Delivers a Presentation on “Lineage Tracing and Stem Cell Research”
Professor Guo Quanyi Delivers a Presentation on “Research Progress in Stem Cell Therapy for Osteoarticular Diseases”
Professor Li Zongjin Presents “Therapeutic Applications of Mesenchymal Stem Cell-Derived Exosome Vesicles in Tissue Injury Repair”
Professor Li Yinping Presents on “Therapeutic Effects of Mesenchymal Stem Cell-Derived Products on Cerebral Ischemia”
Professor Jean François Henri Rossi Delivers a Presentation on “Immune Precision Medicine from Allogeneic Transplantation”
Professor Stéphane BREZILLON presents “Differential MMP-14 targeting by Biglycan, Decorin, Fibromodulin and Lumican Unraveled by In Silico Approach”
Mr. Sun Feng Delivers a Presentation on “Review of Recent Investment and Financing in China’s Cell and Gene Therapy Industry and Future Outlook”
Professor Céline GIGANT Presents “Immune properties of umbilical cord mesenchymal stromal cells in cell therapy context”
Professor Martin VILLALBA GONZÁLEZ Delivers a Presentation on “Non-genetically modified, CAR-like, NK cells”
Director Zhang Delivers a Presentation on the Shanghai Baoshan High-Tech Industrial Park
Professor Wang Yingying Hosts “Cell Industry Innovation and Clinical Translation”
Professor He Zhixu Delivers a Presentation on “Progress in the R&D and Application of CAR-NK Immune Cell Therapy”
Professor Han Zhibo Presents “R&D and Translation of Perinatal Stem Cell Drugs”
Professor Guan Zheng presented “In Vitro and In Vivo Experimental Study on the Osteogenic Differentiation of Dental Pulp Stem Cells on Decellularized Dental Pulp-Coated Chitosan Scaffolds”
Professor Loïc REPPEL presents “Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer”
Professor Zhang Zhiyong Delivers a Presentation on “Research and Development and Translation of the DASEA (Digitalization, Automation, Scalability, Enclosure, and Activation) Bio-Manufacturing Platform for Stem Cells/Exosomes: From Laboratory Research to Clinical Application”
[Roundtable Forum 1] Professor Han Zhibo, Professor Cao Xiaocang, Professor Zhang Lei, Professor Li Zongjin, Professor Zhang Zhiyong, Professor He Zhixu, and Professor Zhang Leisheng Jointly Participated in the Forum on “Industry-Academia-Research Collaboration Facilitating the Translation of Cell-Based Therapies”
Professor Tang Hongming Delivers a Presentation on “Accelerating the High-Quality Development of the Stem Cell Industry to Forge a New Engine for the Bioeconomy”
Professor Zhang Lei Presents “The Current Status and Future of Gene Therapy in China”
Professor Hua Guoqiang Delivers Presentation on “Mechanistic Illustration: How to Use Innovative Combination Therapies to Prevent Newly Formed Blood Vessels from Being Obstructed by Mineral Blocks of Bone Substitutes”
Professor Wu Zhaohui Delivers a Presentation on “Reflections and Responses to Compliance in Stem Cell Sourcing”
Professor Rana SMAIDA shared insights on “Development of an innovative advanced therapy medicinal product combining stem cells and an implantable medical device for regenerative medicine”
Professor Zhou Fuling Delivers a Presentation on “Umbilical Cord Blood Microtransplantation for the Treatment of Elderly Patients with AML”
[Roundtable Discussion II] Themed “Breakthroughs in China’s Cellular Medicine Industry,” with participation from Professor Wang Jialun, Deputy Director Zheng Yang, President Fu Daxu, Lawyer Xu Jingdong, Mr. Shen Jun, Vice Chairman Wu Zhaohui, and Mr. Han Zhihai.
Finally, Mr. Han Zhihai, General Manager of Sinocell Group, delivered a presentation titled “Establishing a National Network of Life Science Popularization Centers Based in Shanghai and Serving the Whole Country.” He elaborated on biomedical technological innovation and research, translation of scientific achievements, Sinocell Group’s responsibilities and vision, and its global network layout, offering attendees fresh perspectives and novel insights for development in related fields.
Closing Ceremony of the Conference
Ms. Yang, Deputy General Manager of Sinocell Group and Founder of IMCELL Health & Aesthetics Space, stated at the forum’s closing ceremony: “Over these brief two days, we have gathered in Baoshan, a land of great promise, where we witnessed its ‘starting with the intensity of a final sprint’ approach to development, as well as its determination and perseverance to support scientific and technological innovation so that it may bear greater industrial fruit and flourish. The agenda over these two days was both pragmatic and comprehensive, allowing us to see the robust growth and promising future of the regenerative medicine industry. As the conference draws to a close, let us jointly express our hope that leading technologies in the cell industry and new preventive healthcare services will reach households across the nation, bringing benefits to more people.”
Conference Group Photo
“The 1st Forum on Cellular Biopharmaceutical Technology and Industrial Development” aligns closely with the strategic positioning of Baoshan High-Tech Zone. The cell and gene therapy industry has experienced rapid growth in recent years, with cell therapy technologies becoming increasingly refined. Developing this sector is not only essential for economic growth but also crucial for ensuring people’s healthy and fulfilling lives. By seizing this timely opportunity, Baoshan District and Sinocelltech Group will provide entrepreneurs with broader development prospects and higher-quality services, empowering them to achieve greater distance, stability, and success on their entrepreneurial journeys.
Sinocelltech Shanghai Baoshan Base
Hanshi Ark is a platform for health science popularization and cell technology services, built by Sinocell Group to meet human health needs. By establishing an online experience platform and offline science popularization centers, it adopts an integrated online-to-offline (O2O) model to provide users with comprehensive health management services and diverse, one-stop health management solutions.
Drawing on modern preventive medicine, integrating the traditional Chinese medicine concept of “treating disease before it arises,” and incorporating cellular regenerative medicine, Han’s Ark is committed to promoting life and health by maintaining cellular integrity, delaying cellular aging, and ensuring holistic well-being, thereby safeguarding the health of you and your family.
